AveXis
Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.
Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.
AveXis is a biotechnology startup specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly. Founded in 2013, the company was later acquired by Novartis on May 14, 2018, and adopted the name Novartis Gene Therapies in 2020. AveXis focuses on developing and bringing to market innovative gene therapies for individuals and families impacted by rare and severe neurological genetic disorders. The company received a $100.00K grant investment on 01 January 2019 from the North Carolina Biotechnology Center. Specializing in the biotechnology and health care industries, AveXis has shown potential for addressing critical medical needs through advanced genetic therapies.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $100.00K | 1 | North Carolina Biotechnology Center | 01 Jan 2019 |
| Series D | $65.00M | 9 |
|
08 Sep 2015 |
| Series C | $10.00M | - | 09 Jan 2015 | |
| Series B | Unknown | - | 22 Apr 2014 | |
| Series A | Unknown | - | 27 Jul 2013 |
No recent news or press coverage available for AveXis.
We care about your data, and we'd love to use cookies make your experience better.
